Production (Stage)
Elite Pharmaceuticals, Inc.
ELTP
$0.517
-$0.0022-0.42%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 122.75% | -23.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 122.75% | -23.92% | |||
| Cost of Revenue | 78.31% | -22.82% | |||
| Gross Profit | 182.63% | -25.35% | |||
| SG&A Expenses | -25.35% | 20.17% | |||
| Depreciation & Amortization | -5.23% | 2.90% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.02% | -13.83% | |||
| Operating Income | 1,062.06% | -68.50% | |||
| Income Before Tax | 280.91% | -11.91% | |||
| Income Tax Expenses | 850.75% | -84.23% | |||
| Earnings from Continuing Operations | 256.06% | 1.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 256.06% | 1.31% | |||
| EBIT | 1,062.06% | -68.50% | |||
| EBITDA | 760.42% | -60.81% | |||
| EPS Basic | 255.88% | 0.97% | |||
| Normalized Basic EPS | 296.77% | -10.71% | |||
| EPS Diluted | 255.88% | 0.97% | |||
| Normalized Diluted EPS | 296.77% | -10.71% | |||
| Average Basic Shares Outstanding | 0.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||